DUBLIN, July 8, 2016 /PRNewswire/ —
Study and Areas has introduced the inclusion of the “Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update” report for their offering.
This Aggressive Intelligence statement about Biosimilar & Biosuperior Therapeutic Antibodies changes the competitive landscape of biosimilar beneficial antibodies by May 2016. The statement examines the very first influx of biosimilar recombinant monoclonal antibodies when comparing to the related inventor antibodies and biosuperior antibodies from the same target.
Study and Areas
Laura Wood, Mature Director